Head-To-Head Review: Osmotica Pharmaceuticals (NASDAQ:OSMT) versus Acerus Pharmaceuticals (NASDAQ:TRLPF)

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Volatility & Risk

Osmotica Pharmaceuticals has a beta of 3.75, indicating that its stock price is 275% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Osmotica Pharmaceuticals and Acerus Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osmotica Pharmaceuticals 0 1 4 0 2.80
Acerus Pharmaceuticals 0 0 0 0 N/A

Osmotica Pharmaceuticals currently has a consensus price target of $8.40, indicating a potential upside of 23.53%. Given Osmotica Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Osmotica Pharmaceuticals is more favorable than Acerus Pharmaceuticals.

Valuation and Earnings

This table compares Osmotica Pharmaceuticals and Acerus Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals $240.03 million 1.46 -$270.90 million $0.25 27.20
Acerus Pharmaceuticals $7.38 million 1.40 -$18.79 million N/A N/A

Acerus Pharmaceuticals has lower revenue, but higher earnings than Osmotica Pharmaceuticals.

Institutional & Insider Ownership

14.4% of Osmotica Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Acerus Pharmaceuticals shares are held by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Osmotica Pharmaceuticals and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals -115.34% -6.22% -1.97%
Acerus Pharmaceuticals -254.66% -346.72% -94.54%


Osmotica Pharmaceuticals beats Acerus Pharmaceuticals on 10 of the 11 factors compared between the two stocks.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply